WO1999055728A2 - Ese genes and proteins - Google Patents
Ese genes and proteins Download PDFInfo
- Publication number
- WO1999055728A2 WO1999055728A2 PCT/CA1999/000375 CA9900375W WO9955728A2 WO 1999055728 A2 WO1999055728 A2 WO 1999055728A2 CA 9900375 W CA9900375 W CA 9900375W WO 9955728 A2 WO9955728 A2 WO 9955728A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- sequence
- esel
- ese
- ese2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- This invention relates to novel mammalian proteins encoded by the Esel and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton.
- Endocytosis via clathrin-coated pits is a multipstep process (1, 2).
- Clathrin heavy and light chains are brought to the plasma membrane through association with a heterotetrameric complex known as clathrin adaptor complex 2, or AP-2.
- AP-2 a heterotetrameric complex
- the membrane is bent through the assembly of clathrin triskelion into a caged lattice.
- the GTPase Dynamin is also recruited to the neck of coated pits where it assembles into a collar for vesicle fission (4, 5).
- Epsl 5 protein was discovered in a search for substrates of the Epidermal Growth Factor Receptor (26). In 1995, Benmerah et. al. reported that Epsl5 is constitutively associated with ⁇ -adaptin of the AP2 complex (27). The Epsl 5 protein has also been localized to the neck of clathrin-coated pits by immunoelectron microscopy (28, 29). Recently, two groups have used dominant inhibitory mutants of Epsl5, or antibodies against Epsl5 (or the related protein Epsl5R), to demonstrate that Epsl5 proteins are required for endocytosis via clathrin-coated pits (30, 31). Epsl 5 contains three large structural domains (26, 32). The N-terminal third contains three copies of an EH domain (for Epsl 5 Homology domain) (32, 33). The central region of Epsl 5 forms an extended coiled-coil, which is followed by a complex C-
- Epsl5R SUBSTTTUTE SHEET (RULE 26) terminus containing SH3-binding motifs (34), a large number of DPF repeats (Aspartic acid-Proline-Phenylalanine), and ⁇ -adaptin binding sequences (31, 35, 36).
- the full length Epsl5R protein has a similar overall organization (34). Both Epsl 5 and Epsl5R can be alternatively spliced to produce numerous smaller proteins(37). A protein with similar overall organization has been identified in
- Panlp Saccharomyces cerevisiae named Panlp. Genetic analysis of PAN 1 has revealed that this gene is required for endocytosis and for organization of the actin cytoskeleton (23, 38). Like Epsl5 and Epsl5R in mammals, the Panlp protein has N-terminal EH domains followed by a central coiled-coil domain and C-terminal proline-rich sequences. A second EH domain containing protein, End3p, has also been described in S. cerevisiae which is required for endocytosis and regulation of the actin cytoskeleton (21, 39). Co-immunoprecipitation studies have shown that Panlp and End3p form a complex in vivo (40) .
- End3p can suppress the phenotype of pan 1-4 hypomorphic mutants, and Panlp is mislocalized in end3 mutants indicating that these proteins function together (40).
- Additional studies have revealed that the EH domains of Panlp bind to yeast homologues of mammalian clathrin-binding proteins, API 80 and CALM (yAP180A and yAP180B), through NPF motifs (Asparagine-Proline-Phenylalanine) in the yAP180 C-termini(25). These data have led to a proposal that the Panlp:End3p complex functions as a multivalent adaptor to coordinate protein-protein interactions during endocytosis (25, 40).
- At least two additional proteins are predicted to bind to the Panlp:End3p complex in vivo, as strong genetic interactions have been detected between PAN1 and SJL1(25), and between PAN1 and RSP5 (41).
- SJL1 encodes a phosphatidylinositol polyphosphate-5-phosphatase protein which is related to mammalian synaptojanin (42) and has a C-terminal NPF motif predicted to bind to EH domains in Panlp (or End3p) (25, 43) .
- RSP5 encodes an E3 ubiquitin-protein ligase which may bind to the C-terminal polyproline sequences in Panlp through one of its three WW domains (25).
- SH3 domain containing proteins have been implicated in the regulation of endocytosis (44). These include Amphiphysin 1(45) and II (6, 46, 47, 48), Rsvl61/Rsvl67(7), Actin Binding Protein- 1(49), Endophilin/SH3P4/8/13 (50, 51) and Grb2 (52). Kay and coworkers have reported the isolation of several novel SH3 encoding cDNAs (53).
- the present inventors have identified novel mammalian proteins containing both EH and SH3 domains, which have been named Esel and Ese2. Sequence and functional analysis of the full length proteins have implicated these proteins in receptor mediated endocytosis via clathrin coated pits and therefore the proteins have been named Esel and Ese2 respectively (Ese: for EH-domain and SH3 domain regulator of Endocytosis). Also identified are several mammalian alternative transcript proteins two of which are named EselL and Ese2L.
- this invention provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mammalian Esel and Ese2 proteins.
- the invention more specifically provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mouse Esel and Ese2 proteins.
- the mammalian polynucleotide may be in the form of DNA, genomic DNA, cDNA, mRNA and various fragments and portions of the gene sequence encoding Ese proteins.
- Homologues of the mammalian Ese protein genes are generally those sequences which share at least 80% sequence identity, preferably at least 90% sequence identity to the mammalian Ese gene sequence.
- the invention provides cDNA sequences encoding murine Esel and Ese2 proteins comprising the nucleotide sequences of Sequence ID NOS: 1, 2, 4 and 5.
- the invention provides cDNA sequences encoding murine EselL and Ese2L proteins comprising the nucleotides sequences of Sequence ID NOS: 22, 23, 25 and 26.
- the Ese gene sequences useful as probes or PCR primers or for encoding fragments, functional domains or antigenic determinants of Ese proteins.
- the probes can be routinely used to screen and identify homologues of the Ese gene or portions thereof while primers are useful in PCR assays for the amplification of desired portions of the selected Ese gene.
- the invention also provides portions of the disclosed nucleic acid sequences comprising about 10 consecutive nucleotides to nearly the complete disclosed nucleic acid sequences.
- the invention provides isolated nucleic acid sequences comprising sequences corresponding to at least 10, preferably 15 and more preferably at least 20 consecutive nucleotides of the Ese genes as disclosed or enabled herein or their complements.
- the isolated nucleic acids of the invention include any of the above described nucleotide sequences included in a vector.
- Expression vectors comprising the nucleotide sequences are provided along with suitable host cells transfected with such expression vectors.
- this invention provides substantially pure mammalian Ese proteins, fragments of these proteins and fusion proteins including these proteins and fragments.
- this invention provides substantially pure mutant mammalian Ese proteins, fragments of these proteins and fusion proteins including these mutant proteins and fragments.
- the invention provides amino acid sequences encoding murine Esel and Ese2 proteins comprising the amino acid sequences of Sequence ID NOS: 3 and 6.
- the invention provides amino acid sequences encoding murine EselL and Ese2L proteins, which are alternative transcripts, comprising the amino acid sequences of Sequence ID NOS: 24 and 27.
- the proteins, fragments and fusion proteins have utility, as described herein, for the preparation of polyclonal and monoclonal antibodies to murine and mammalian Ese proteins, for the identification of binding partners of the mammalian Ese proteins and for diagnostic and therapeutic methods, as described herein.
- the present invention provides substantially pure proteins, polypeptides or derivatives of polypeptides which comprise portions of the mammalian Ese amino acid sequences disclosed or enabled herein and which may vary from about 4 to 5 amino acids to the complete amino acid sequence of the proteins.
- the invention provides substantially pure proteins or polypeptides comprising sequences corresponding to at least 5, preferably at least 10 and more preferably 50 or 100 consecutive amino acids of the mammalian Ese proteins disclosed or enabled herein.
- Monoclonal antibodies having suitably specific binding affinity for the antigenic regions of a mammalian Ese protein are prepared by the use of corresponding hybridoma cell lines.
- polyclonal antibodies may be prepared by inoculation of animals with suitable peptides which add suitable specific binding affinities for antigenic regions of an Ese protein.
- a process for producing mammalian Ese proteins comprising culturing one of the above described transfected host cells under suitable conditions, to produce the Ese protein by expressing the DNA sequence.
- the proteins of the invention may be isolated and purified by any conventional method suitable in relation to the properties revealed by the amino acid sequences of these proteins.
- cell lines may be produced which express or over-express the Ese gene products, allowing purification of the proteins for biochemical characterisation, large-scale production, antibody production and patient therapy.
- eukaryotic or prokaryotic expression systems may be generated in which an Ese gene sequence is introduced into a plasmid or other vector which is then introduced into living cells. Constructs in which the Ese cDNA sequences containing the entire open reading frame is inserted in the correct orientation into an expression plasmid may be used for protein expression. Alternatively, only portions of the sequence may be inserted.
- Prokaryotic or eukaryotic expression systems allow various important functional domains of the proteins to be recovered as fusion proteins and used for binding, structural and functional studies and also for the generation of appropriate antibodies.
- the present invention includes effective fragments, analogues of the Ese proteins described herein.
- Effective fragments or analogues retain the activity of the described Ese proteins to regulate endocytosis, vesicular trafficking and actin dynamics.
- analogue extends to any functional and/or chemical equivalent of a mammalian Ese protein including mimetics and includes proteins having one or more conservative amino acid substitutions, proteins incorporation unnatural amino acids and proteins having modified side chains.
- antibodies are enabled which bind specifically to the Ese proteins disclosed herein.
- Polyclonal or monoclonal antibodies may be prepared using conventional methods.
- Antibodies may also be prepared to individual selected domains of the Ese proteins, as described herein.
- the invention provides pharmaceutical compositions containing an Ese protein, fragment or mimetic thereof or a non- functional mutant Ese protein, fragment or mimetic thereof for the treatment of mammalian disorders which involve abnormal endocytosis, vesicular trafficking and actin dynamics leading to altered cellular functioning.
- Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result.
- the composition comprises an Ese protein and a pharmaceutically acceptable carrier.
- the invention provides a method for identifying binding partners of the Ese proteins disclosed herein.
- Such methods in general include various assays including those including radiolabelling of the Ese proteins.
- Other methods may include but are not restricted to phage display, affinity purification techniques, expression cloning and the yeast 2-hybrid system, as described herein.
- the identification of proteins or peptides interact with or bind to Ese proteins can provide the basis for the design of peptide antagonists or agonists of Ese protein function or for the design of peptide antagonists or agonists of Ese protein binding partners which affect Ese protein function. Further, the structure of these peptides determined by standard techniques such as protein NMR or x-ray crystallography can provide the structural basis for the design of improved small molecule drugs.
- the present invention also provides for the production of mouse models or transgenic non-human animal models for the study of mammalian Ese gene function, for the screening of candidate pharmaceutical compounds, for the creation of in vitro mammalian cell cultures which express the Ese proteins or in which an Ese gene has been inactivated by knock-out deletion, and for the evaluation of potential therapeutic interventions.
- the invention enables a transgenic animal, including a transgenic insect, wherein the genome of the animal or of an ancestor of the animal has been modified by introduction of a transgene comprising mammalian Ese genes under the transcriptional control of tissue restricted regulatory elements including the mouse mammary-tumour virus long term repeat sequences.
- Transgenic animals with inappropriate expression of Ese proteins may be examined for phenotypic changes, for example abnormal cellular development or abnormal cellular signalling, vesicular trafficking and actin dynamics and may be used to screen for compounds with potential as pharmaceuticals. Compounds which provide reversal of the phenotypic changes are candidates for development as pharmaceuticals.
- Transgenic animals in accordance with the invention can be created by introducing a DNA sequence encoding a selected Ese protein either into embryonic stem (ES) cells of a suitable animal such as a mouse, by transfection or microinjection, or into a germ line or stem cell by a standard technique of oocyte microinjection.
- ES embryonic stem
- a suitable animal such as a mouse
- transfection or microinjection or into a germ line or stem cell by a standard technique of oocyte microinjection.
- Such methods of producing animal models are fully described in the literature.
- a method for screening a candidate compound for effectiveness as an antagonist of an Ese protein comprising:
- a method for treating in a mammal a disorder associated with an undesired level of endocytotic activity of an Ese protein comprising administering to the mammal an effective amount of a substance selected from the group consisting of: (a) an Ese protein antagonist; (b) an antibody which binds specifically to an Ese protein;
- an antisense strand comprising a nucleic acid sequence complementary to the sequence or fragment of the sequence and capable of hybridizing to the nucleic acid sequence encoding an Ese protein
- According to another aspect of the present invention is a method for suppressing in a mammal, the abnormal proliferation of a cell capable of being stimulated to proliferate by a growth factor receptor, the method comprising administering to the mammal an effective amount of a Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein.
- According to yet another aspect of the present invention is a method for preventing viral infection in a mammal, said method comprising administering to the mammal an effective amount of an Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein or an Ese mutant protein not capable of regulating endocytosis.
- a method for promoting endocytosis, vesicular trafficking and/or actin dynamics in selected cells in a mammal in need of such treatment comprising administering to the mammal an effective amount of an Ese protein or an active analogue, mimic or fragment thereof.
- a method for blocking clathrin-mediated endocytosis in cultured cells or in selected cells in a mammal in need of such treatment comprising overexpressing Esel protein or an active analogue, mimic or fragment thereof.
- a further aspect of the present invention is a method for regulating endocytosis, vesicular trafficking and/or actin dynamics in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising providing an Esel-Eps 15 complex and further providing a protein binding partner to bind to the complex to regulate components of the endocytic pathway.
- a protein binding partner is dynamin.
- Table 1 shows alignment of mouse Esel and Ese2 protein sequences. EH, coiled-coil and SH3 domains are as indicated.
- Table 2 shows the alignment of protein sequences of the Ese family in mouse
- Figure 2A shows Western blots demonstrating the association of Ese and
- Epsl 5 proteins in vivo Endogenous Esel proteins were precipitated with Rabbit anti- peptide antisera against the N-terminus of Esel . Imrnunoprecipitates were then analyzed on western blots for the presence of Ese 1/2 with Chicken anti-Ese antisera or for co-precipitation of Epsl 5 with Rabbit antisera raised against the C-terminus of
- FIG. 2B shows alternative transcripts from the Esel and Ese2 genes which code for EselL and Ese2L proteins respectively, with C-terminal DBL/PH and C2 domains. Esel and Ese2 sequence junctions are indicated in bold red letters.
- Figure 3 A shows Ese and Epsl 5 associate in vivo. This schematic representation of association of Eps 15/Eps 15R with Ese 1 in the yeast two-hybrid screen. Esel coiled-coil domain fused with the Gal4 DNA binding domain (DBD) interacted with Epsl5/Epsl5R Gal4 activation domain (AD) fusions. The AD- Epsl5 Epsl5R diagram represents the shortest interacting coding region isolated.
- DBD Gal4 DNA binding domain
- AD Epsl5/Epsl5R Gal4 activation domain
- Figure 3B shows association of Ese and Epsl 5 C-terminal deletion mutants.
- Cos-1 cells were transfected with pcDNA3Epsl5, pcDNA3Esel or the C-terminal deletion mutants pcDNA3Esel ⁇ C and pcDNA3Epsl5 ⁇ C-Flag as indicated.
- Cell lysates were immunoprecipitated with rabbit anti-Ese 1 or rabbit anti-Epsl5 (left panel); rabbit anti-Ese 1, mouse anti-Flag or rabbit anti-Epsl5 (right panel). Panels represent western blots to detect the presence of Esel in each immunoprecipitation.
- a 90kDa Esel protein exists in the third and sixth lanes on the left panel which is the C- terminally truncated Esel protein which is co-immunoprecipitated in a complex with Eps 15 in the sixth lane. Also, to be noted is the precipitation of Esel with anti-Flag monoclonal antibody in the sixth lane of the right panel experiment. In this case, Esel has been precipitated in a complex with the C-terminally truncated Epsl5 ⁇ C protein.
- Figure 4 shows confocal immunofluorescent micrographs of Cos cells transfected with myc-Esel (A, A'); Epsl5 (B); myc-Esel + Epsl5 (C, C ⁇ C " ) or myc-Esel + Epsl5 ⁇ C (D, D' and D").
- Frames C" and D' represents the overlapping images from frames C/C and D/D', respectively. Overlap in frames C" and D" are indicated in yellow. Scale bar is equal to 10 microns.
- Figure 5 A and 5B show that Esel links to Dynamin and Epsl 5.
- Figure 5 A is a schematic representation of association between Dynamin and Esel in the yeast two- hybrid screen.
- FIG. 5B shows confocal immunofluorescent microscopy to detect transfected mycEsel (frame a), transfected Eps 15 (frame d) or endogenous Dynamin (frames b and e) in transfected Cos cells.
- Frame c and f represents the overlapping images from frames a/b and d/e respectively. Scale bar is equal to 10 microns.
- FIG. 6 shows Esel overexpression blocks endocytosis of Transferrin in Cos- 1 cells. Confocal immunofluorescent microscopy was used to detect transfected mycEsel (frame A), internalized FITC-labeled Transferrin (frame B). Overlapping images are shown in frame C revealing that Esel overexpression blocks clathrin-
- SUBSTJ ⁇ UT ⁇ SHEET (RULE 26 mediated endocytosis of Transferrin. Mononuclear morphologically normal cells from both transfected and untransfected groups where assessed for internalization of transferrin. Scale bar is equal to 10 microns.
- Figure 7 shows a proposed model for Ese regulation of Endocytosis.
- preferred embodiments of the invention are illustrated by way of example. It is to be expressly understood that the description and drawings are only for the purpose of illustration and as an aid to understanding, and are not intended as a definition of the limits of the invention.
- the full length murine Esel cDNA was sequenced (Sequence ID NO:l). It encodes a sequence of 1213 amino acids (Sequence ID NO:3) having a predicted molecular weight of 137 kDa.
- Murine Ese2 cDNA was also sequenced (Sequence ID NO:4) and encodes a sequence of 1197 amino acids (Sequence ID NO:6) having a predicted molecular weight of 135.7 kDa.
- Ese proteins are predicted to encode two N-terminal EH domains followed by a coiled-coil domain and five SH3 domains (Tables 1 and 2).
- Several Esel isolated clones contain only SH3 A , SH3 B and SH3 E domains. Indeed, the SH3 C domain was not included in the original human SH3P17 partial cDNA.
- expressed sequence tags from the Esel gene have been found in the public databases which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene is subject to complex alternative splicing and has the potential to encode for many distinct proteins.
- the predicted Ese2 protein encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, suggesting that this gene is also alternatively spliced.
- the Ese proteins are 53% identical over the full length of Esel (645 of 1213 residues in Esel line up with identical residues in Ese2) and are related to the Ese protein from Xenopus which has recently been submitted to genebank (Accession # AF032118) and Drosophila (59) (Table 2).
- Xenopus Intersectin is 81% identical to mouse Esel and 54% identical to mouse Ese2 suggesting that Intersectin is an Esel orthologue (980/1213 residues of mouse Esel and 645/1198 residues of mouse Ese2 line up with identical residues in the Xenopus protein).
- Drosophila Dynamin associated protein Dapl60-1 is 32% identical to both mouse Ese proteins (393/1213 residues of mouse Esel and 387/1198 residues of mouse Ese2 line up with identical residues in the Drosophila protein).
- Dap 160-1 has only four SH3 domains corresponding to the first, second, fourth and fifth SH3 domains of the mouse Ese proteins. Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites and at least one SH3 -binding consensus (60) in the N-terminus of each Ese protein.
- the two EH domains of Esel are highly related to the respective EH domains in Ese2 and these Ese EH domains are most closely related those found in Eps 15 and Epsl5R, two mammalian protein which are required for endocytosis through clathrin- coated pits. EH domains have also been identified in End3 and Panlp which are yeast partners proteins required for endocytosis. The central third of both Ese proteins are predicted to encode an extended coiled-coil which is a domain typically associated with protein-protein association through dimerization or tetramerization as noted for Eps 15 (29, 54).
- the Esel SH3 domains are most closely related to SH3 domains from Myosin IB in Acanthamoeba (SH3 A ), Myosin IB in Entamoeba (SH3 B ), the YFR024 hypothetic yeast protein
- SH3 C Myosin IB from Acanthamoeba
- SH3 D Myosin IB from Acanthamoeba
- SH3 E Myosin IC from Acanthamoeba
- SH3 A which is most similar to the SH3 domain from ⁇ PIX
- SH3 C which is most similar to an SH3 domain from the mouse Ray protein
- SH3 D which is most similar to the SH3 domain from Dictyostelium myosin IB.
- Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites in the Ese proteins and a single SH3 binding consensus in the N-termini of each Ese protein.
- antibodies which recognize epitopes within these proteins and which can be raised to provide information on the characteristics of the protein as well as for any mutant form of these proteins.
- the generation of antibodies enables the visualization of the protein in mammalian cells and tissues using Western blotting as described herein.
- Antibodies to the Esel or Ese2 proteins also allows for the use of immunocytochemistry and immunofluorescence techniques in which the proteins are visualized directly in cells and tissues as described herein. This is most helpful in order to establish the subcellular location of the protein and the tissue specificity of the protein. In general, methods for the preparation of antibodies are well known.
- fusion proteins containing defined portions or all of the Esel or Ese2 proteins or any of their alternative transcripts can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle.
- the protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and injected into rabbits or other laboratory animals.
- protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use, by affinity chromatography.
- the sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the Esel or Ese2 protein, alternative transcript or any mutant thereof.
- synthetic peptides can be made to the antigenic portions of these proteins and used to innoculate the animals.
- tissue culture wells in the presence of a selective agent such as HAT.
- the wells are then screened to identify those containing cells making useful antibody by ELISA. These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells.
- Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable lines of clones is established which produce the antibody.
- the monoclonal antibody can then be purified by affinity chromatography using Protein A or Protein G Sepharose.
- the Ese proteins may be isolated and purified by methods selected on the basis of properties revealed by its sequence. Purification can be achieved by protein purification procedures such as chromatography methods (gel-filtration, ion-exchange and immunoaffinity), by high-performance liquid chromatography (HPLC, RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing and hydrophobic interaction chomatography) or by precipitation (immunoprecipitation). Polyacrylamide gel electrophoresis can also be used to isolate the Ese proteins based on the molecular weight of the protein, charge properties and hydrophobicity.
- the purified proteins can be used in further biochemical analyses to establish secondary and tertiary structure which may aid in the design of pharmaceuticals to interact with the protein, alter the protein charge configuration or charge interaction with other proteins or alter its function.
- the Ese proteins can also be purified from the creation of fusion proteins which are expressed and recovered from prokaryotic or eukaryotic cells.
- the fusion proteins can be purified by affinity chromatography based upon the fusion vector sequence.
- the Ese protein can then be further purified from the fusion protein by enzymatic cleavage of the fusion protein.
- the Northern blot reveals the presence of many alternative mRNA transcripts for both Esel and Ese2.
- numerous Esel expressed sequence tags have been identified which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene has the potential to encode for many distinct proteins.
- the SH3 C domain was spliced out of the human SH3P17 partial cDNA described by Sparks 1996 (53).
- the predicted Ese2 protein on the other hand encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, revealing that this gene is also alternatively spliced.
- C2 domains are Ca +" activated membrane binding domains and protein- protein interaction domains (62).
- a number of expressed sequence tages which code for a novel C2 domain fused to the sequence coding for the last 11 amino acids of Ese2 have been identified. PCR was used to isolate sequences coding for alternatively spliced exon(s) which can be included C-terminal to the SH3 domains but before the stop codon.
- the alternatively spliced exon(s) of Ese2 also code for a DBL/PH + C2 domain cassette which can be included within the Ese2 transcript ( Figure 2B).
- the Ese genes are subject to complex alternative splicing to produce proteins with novel predicted functions (eg. regulation of the cytoskeleton and membrane-binding), the alternative proteins are named as modifications of Ese.
- the Esel and Ese2 long forms described in Figure 2B are called EselL and Ese2L, respectively.
- the name is listed as an Ese ⁇ variant.
- the protein encoded by the spliced variant in the original SH3P17 clone is designated as Esel ⁇ S c to indicate removal of SH3 C .
- the knowledge of the Esel and Ese2 gene sequences and their expression in heterologous cell systems can be used to demonstrate structure-function relationships as well as provide for cell lines for the purposes of drug screening.
- Ligating the Esel or Ese2 cDNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates, binding partners as well as activators and inhibitors of the proteins.
- Plasmid expression vectors containing either the entire, or portions thereof, Esel or Ese2 can be used in in vitro mutagenesis experiments which will identify portions of the protein crucial for regulatory function.
- the Esel or Ese2 cDNA sequence (or EselL and Ese2L cDNA sequence) can be any Esel or Ese2 cDNA sequence.
- SUBSTJTTUTE SHEET (RULE 26 be manipulated in studies to understand the expression of the gene and its product, to achieve production of large quantities of the protein for functional analysis, for antibody production, and for patient therapy. The changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties. Partial or full-length cDNA sequences which encode for the Esel or Ese2 protein (or alternative transcripts thereof), modified or unmodified, may be ligated to bacterial expression vectors.
- E. coli can be used using the T7 RNA polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with Ml 3 Phage mGPI-2.
- E. coli can be used using the T7 RNA polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with Ml 3 Phage mGPI-2.
- coli vectors can also be used with Phage lamba regulatory sequences, by fusion protein vectors (eg. lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.
- fusion protein vectors eg. lacZ and trpE
- maltose-binding protein fusions e.g. glutathione-S-transferase fusion proteins.
- the Ese 1 or Ese2 protein or alternative transcripts thereof can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus.
- the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long- term expression.
- SV40 simian virus
- the stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin, G418 and purimycin.
- Esel or Ese2 cDNA sequences can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.
- the cDNA sequence or portions thereof, or a mini gene consisting of a cDNA with an intron and its own promoter is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation.
- the endogenous Esel or Ese2 gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression of the cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid- responsive promoter from the mouse mammary tumor virus.
- Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.
- Vectors are introduced into recipient cells by various methods including calcium phosphate, electroporation, lipofection, DEAE dextran, microinjection, or by protoplast fusion.
- the cDNA can be introduced by infection using viral vectors.
- Eukaryotic expression systems can be used for many studies of the Esel or Ese2 gene and gene product(s) including determination of proper expression and post- translational modifications for full biological activity, identifying regulatory elements located in the 5' region of the Esel or Ese2 gene and their role in tissue regulation of protein expression, production of large amounts of the normal and mutant protein for isolation and purification, to use cells expressing the Esel or Ese2 protein or alternative transcripts thereof as a functional assay system for antibodies generated against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring and artificially produced mutant proteins.
- the expression vectors containing the Esel or Ese2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells. It is understood that the cDNA sequences for use in the present invention include those sequences disclosed herein encoding Esel, EselL, Ese2 and Ese2L proteins.
- the recombinant cloning vector comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host.
- the DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that Esel or Ese2 proteins or alternative transcripts thereof can be expressed.
- the expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof.
- the expression control sequence may be selected from the group consisting of the lac system, the tip system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.
- the host cell which may be transfected with the vector of this invention may be selected from the group consisting of E.coli, pseudomonas, bacillus subtillus, bacillus stearothermophilus, or other bacili; other bacteria, yeast, fungi, insect, mouse or other animal, plant hosts, or human tissue cells.
- Esel overexpressed in 10T1/2, BHK and Hela cells using the vaccinia virus T7 expression system is also localized to large circular domains (data not shown).
- This concentration of ectopically expressed Esel contrasts with the localization of Eps 15 in transiently transfected cells, Eps 15 being dispersed throughout the cell ( Figure 4B).
- Esel and Eps 15 proteins form a complex in vivo and yet localize to distinct subcellular compartments in transfected Cos cells. We therefore determined the localization of both mycEsel and Eps 15 in Cos cells co- transfected with both genes. In co-transfected cells, mycEsel is still found in circular domains ( Figure 4C).
- Eps 15 is now also partially co- localized with Esel in the same circular domains ( Figure 4C and C").
- the C-terminal third of Eps 15 contains several regions which are required for association with ⁇ -adaptin of the AP2 clathrin adaptor complex (31). It has been shown that this region of Eps 15 is not required for its association with Esel ( Figure 4).
- mycEsel and Epsl5 ⁇ C have been co-transfected.
- Prey plasmids were recovered from 37 positive yeast colonies which were selected for expression of both His3 and LacZ.
- Several classes of cDNA were recovered in this screen.
- One class included Eps 15 which was isolated twice and Epsl5R which was isolated from four yeast colonies.
- Epsl5R which was isolated from four yeast colonies.
- these clones were all partial cDNA fusions which minimally included C- terminal sequences from the central coiled-coil domain to the 3"UTR ( Figure 3 A).
- Eps 15 the positive clones start from amino acid 306 and 376 whereas in Epsl5R the N-terminal boundary of clones were amino acid 4, 10, 222 and 386.
- the Ese proteins were analyzed in vivo to test for their association with Eps 15 or Epsl5R.
- Polyclonal antisera were raised in chickens against a GST fusion containing the C-terminus of Esel from amino acid 665 to the stop codon. This region of Esel contains all five of the SH3 domains.
- polyclonal antisera were generated in rabbits against a peptide representing the first 21 amino acids of Esel.
- Cell lysates were prepared from A431, PC 12, MDCK and Hela cells which represent cell lines from several distinct tissue types and species. The rabbit anti- peptide antisera were used to precipitate Esel from each lysate and precipitates were analyzed by western blotting using the chicken anti-Ese sera.
- Esel contains multiple C-terminal SH3 domains while Eps 15 contains SH3-binding motifs.
- C-terminal truncations of each (Epsl5 ⁇ C and Esel ⁇ C) were generated.
- Full length Eps 15 was co-transfected into Cos-1 cells together with either full length Esel or C-terminally truncated Esel ⁇ C.
- Cell lysates were precipitated with either rabbit anti-Epsl5 or with rabbit anti-Ese 1, and precipitates were western blotted with chicken anti Esel antisera.
- the anti-Flag antibody efficiently precipitated Esel from cells expressing Flag-tagged Eps 15 ⁇ C indicating that the C-terminally truncated Eps 15 protein can bind to Esel in vivo.
- the Esel and Eps 15 proteins are therefore associated through interaction of their central coiled-coil regions and do not require the presence of SH3 and SH3-binding motifs in their respective C-termini.
- Ese binding proteins TSG101 (accession #U52945), meningioma expressed antigens 6/11 (accession #U94780 for mea6), ⁇ -tropomyosin, rabaptin5 (accession #D86066), Adora2a (accession #Y 13345), LI lipid binding protein (accession #K02109) and numerous cytokeratins and laminins. Novel genes identified in this screen are detailed below.
- the Ese-binding proteins identified in our SH3 screen were the cbl-b oncoprotein (accession #U26712), Dynamin II (accession #L31398), KIAA0268 (accession #D87742), Jerky (accession #U35730), hnRNP-K (accession #L29769), SAP49
- Endogenous Dynamin was not concentrated and was therefore not visable in Eps 15 transfected cells (data not shown).
- Eps 15 and endogenous Dynamin are colocalized on the Esel induced circles ( Figure 5, panels d, e and f) indicating that all three proteins co- localize at these structures.
- Epsin-family protein a novel Epsin-family protein (63, 64).
- This cDNA has been independently isolated and named Ibp-2 in accession #AF057286.
- the Ibp2 clone which has been identified includes amino acids 326 to 509 of the partial coding sequence in Genbank.
- Each Epsin family protein which has been isolated contains a C-terminal region which codes for three copies of an NPF motif. This is also the region of Epsin which binds to Eps 15. It has previously been shown that AP-2 can independently bind both Epsin and Eps 15.
- Epsin family proteins can bind not only to the EH domains of Eps 15 but also to the EH domains of Esel.
- Epsin proteins exist in the Ese:Epsl5 complex or the interaction between individual proteins in various AP- 2:Epsin:Epsl5:Ese:Dynamin complexes may be subject to dynamic rearrangement during clathrin coated pit formation, invagination and scission. Also identified was a mammalian homologue of drosophila. SINA, seven in absentia. Esel Overexpression Blocks Endocytosis
- Panlp Overexpression of Panlp in yeast induces phenotypes which are identical to those observed in panl loss-of-fucntion mutants (65) suggesting that by altering the relative ratios of Panlp to its numerous partners, the function of higher order Panlp complexes may be blocked.
- Ese:Epsl5 complex contains many protein-protein interaction domains which bind partners including Dynamin, Epsin and AP-2, it was thought that overexpressed Esel may disrupt the formation of higher order complexes between Ese proteins and partners. It was therefore tested whether clathrin-mediated endocytosis was functional in myc Esel overexpressing cells. Cos-1 cells were transfected with myc -tagged Esel, and 48 hrs post transfection, FITC-labelled
- the novel Ese proteins of the present invention appear to function to regulate endocytosis involving the formation of clathrin-coated pits by the polymerization of clathrin into a lattice along the cytosolic face of a region of membrane causing the region to expand inward. Ultimately, the pit pinches off from the membrane, and the clathrin cage is completed thus producing a coated vesicle.
- the complex can recruit other proteins such as, Epsin, AP-2 and dynamin and promote coated vesicle formation and perhaps their transport to appropriate locations within the cell and release of internalized proteins and or molecules (Figure 7).
- the SH3 C-terminal domains of the Ese proteins can bind and interact with several other proteins leading to a host of protein-protein interactions involved in subcellular trafficking and signalling.
- the Ese proteins may be activated or inactivated via phosphorylation of the proteins at numerous phosphorylation sites by the action of activated receptors on cell surfaces.
- Ese proteins Due to the fact that the Ese proteins appear to be a key central player in the complex process of endocytosis involving protein-protein interactions and intracellular signalling, these proteins are most likely involved in a myriad of clinical conditions and processes which are very likely to include but not be limited to regulation of endocytosis (as described above), cell division and cancer (Eps 15 and cbl are oncoproteins), cell migration (regulation of the actin cytoskeleton is required for many forms of cell migration), cell polarity, plane of cell division and cell fate specification (Eps 15 binds to Numb in vivo which is required for these processes (43), RNA localization (several RNA binding proteins have been identified in the present screens) and viral infection and life cycle (Eps 15 binds to RAB a cellular cofactor for HIV Rev (43)).
- Ese proteins may play an important role and thus may be a target for developing therapeutic strategies against viral infection and virally-induced disease states.
- HIV is known to alter endocytosis of several important cell surface molecules including CD4 and MHC antigens.
- HIV-NEF has been demonstrated to bind to SH3 domains. NEF induces clathrin coated pit formation. As NEF binds SH3 domains and induces endocytosis, it is possible that Ese proteins may bind to NEF and are involved in NEF function.
- Therapeutic strategies to provide treatment for viral infection and virally induced disease states may therefore include the inhibition of Ese-NEF interactions, antibodies or other agents directed against Ese complexes to inhibit endocytosis and in this manner inhibit viral infection and virally induced disease states. It is also expected that many types of viruses will interact with the multi-component Epsl5-Ese complex.
- Synaptic transmission and abnormal or altered synaptic transmission as seen in various nervous disorders may also be a target for the therapeutic use of Ese proteins and/or antagonists.
- the Epsl5:Ese complex has been demonstrated to regulate endocytosis, is highly expressed in the brain and Ese binds to Jerky; a protein required to prevent epilepsy in mice (57).
- Futhermore Ese proteins are highly expressed not only in the brain but also in the heart and in skeletal muscle which are tissues involving high levels of synaptic transmission. This suggests that Ese protein may be used in the treatment of nervous system disorders involving altered synaptic transmission.
- Receptor-mediated cell signaling such as seen with several different types of growth factors also involves endocytosis.
- Over-expression, mutation or over- stimulation of growth factor receptors has been demonstrated to lead to abnormal cell division and growth as seen in cancer.
- EGF is a potent mitogen for many epithelial cells and EGF receptor activation is known to stimulate intracellular kinase pathways leading to cell proliferation. Such activity may play a role in cancer progression.By altering the rate of endocytosis by targeting Ese proteins, the cell proliferative effect of growth factor receptor stimulation may be counteracted.
- the intracellular cytoskeleton is highly organized and consists of microtubules, microfilaments and intermediate filaments acting as an internal reinforcement in the cytoplasm of a cell. Together these structures associate in a regular and defined manner which is regulated by extracellular signals and may transduce plasma membrane signals by association with other proteins or by second messengers.
- the Ese-Epsl5 complex is very likely to regulate the cytoskeleton by analogy to the role of Panlp:End3p in regulation of yeast cytoskeleton.
- endocytosis is known to involve a rearrangement of the intracellular cytoskeleton. Cell division and migration require the continual rearrangement of the intracellular cytoskeleton.
- abnormal patterns of cell division and migration may involve altered Ese function and altered endocytosis.
- the Ese proteins or the genes may therefore be used to alter regulation of endocytosis or the association of the Ese proteins with the cytoskeleton and may restore cell division and migration to normal levels and patterns.
- Tissue development also involves the continual remodeling of the cytoskeletal network along with its associated proteins.
- Developmental diseases can occur as a result of abnormal remodeling of the cytoskeleton leading to altered intracellular signaling.
- Ese proteins are likely to be involved with both the cytoskeleton and intracellular signaling they may also be directly involved in the development of certain developmental diseases and therefore may be a target for therapeutic treatment of such diseases.
- Ese proteins may also be involved in normal development including that of stem cells which are self-renewing cells that divide to produce differentiated daughter cells in various tissues.
- Ese proteins are associated with the cytoskeleton they may play a part in the formation of certain types of differentiated cells through the partitioning of RNA and proteins such as nuMb during cell division.
- transgenic animal models for abnormal endocytotic function characterized by altered Esel or Ese2 activity is important to the understanding of the function of these proteins in intracellular signaling and for the testing of possible therapies for abnormal endocytosis involving protein-protein interactions and intracellular signalling and leading to various clinical conditions.
- techniques of generating transgenic animals are widely accepted and practiced
- the modifications include insertion of mutant stop codons, the deletion of DNA sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase.
- Gene knockout produces homozygous mutant mice, which show symptoms or phenotype similar to those exhibited by a human.
- embryonic stem cells heterozygous for a knockout mutation in a gene of interest ie. Esel or Ese2 gene
- a marker gene eg. coat colour
- a mutant or normal version of the human Esel or Ese2 gene can be inserted into a mouse germ line using standard techniques of oocyte microinjection or transfection or microinjection into stem cells. Alternatively, if it is desired to inactivate or replace the endogenous Esel or Ese2 gene, homologous recombination using embryonic stem cells may be applied.
- oocyte injection For oocyte injection, one or more copies of a mutant or normal Esel or Ese2 gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of transgenic Esel or Ese2 gene sequences.
- the transgene can be either a complete genomic sequence injected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.
- Retro viral infection of early embryos can also be done to insert the human or mouse Esel or Ese2 gene.
- the Esel or Ese2 gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.
- Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line.
- This methodology is especially useful if inactivation of the Esel or Ese2 gene is desired.
- inactivation of the Esel or Esel gene can be done by designing a DNA fragment which contains sequences from a Esel or Ese2 exon flanking a selectable marker.
- Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the Esel or Ese2 gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.
- This embodiment of the invention has the most significant commercial value as a mouse model for abnormal endocytotic activity and this may include disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic transmission disorders.
- Gene therapy is another potential therapeutic approach for treating disorders involving abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton.
- disorders may include for example but not be limited to disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic transmission disorders.
- Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression.
- the targeted cells however must be able to divide and the expression of the levels or normal protein should be high.
- the full length Ese gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest.
- viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpevirus such as Epstein-Barr virus.
- Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA into a cell. Although these methods are available, many of these are lower efficiency.
- Antisense based strategies can employed to explore mammalian Ese gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary antisense species. The formation of a hybrid RNA duplex may then interfere with the processing/transport translation and/or stability of the target Ese mRNA. Hybridization is required for the antisense effect to occur, however the efficiency of intracellular hybridization is low and therefore the consequences of such an event may not be very successful. Antisense strategies may use a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA and transfection of antisense RNA expression vectors.
- Antisense effects can be induced by control (sense) sequences, however, the extend of phenotypic changes are highly variable. Phenotypic effects induced by antisense effects are based on changes in criteria such as protein levels. Protein activity measurement, and target mRNA levels. Multidrug resistance is a useful model to study molecular events associated with phenotypic changes due to antisense effects, since the multidrug resistance phenotype can be established by expression of a single gene mdrl (MDR gene) encoding for P- glycoprotein.
- MDR gene mdrl
- Transplantation of normal genes into the affected area of the patient can also be useful therepy for any disease condition which includes abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton.
- a normal human Ese gene is transferred into a cultivatable cell type, either exogenously or endogenously to the patient. These cells are then injected serotologically into the disease-affected tissue or tissues.
- Immunotherapy is also possible for treating disorders which includes abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton.
- Antibodies are raised to a mutant Ese protein (or a portion thereof) and are administered to the patient to bind or block the mutant protein and prevent its deleterious effects. Simultaneously, expression of the normal protein product could be encouraged. Alternatively, antibodies are raised to specific complexes between mutant or normal Ese proteins and their binding partners.
- a further approach is to stimulate endogenous antibody production to the desired antigen.
- Administration could be in the form of a one time immunogenic preparation or vaccine immunization.
- An immunogenic composition may be prepared as injectables, as liquid solutions or emulsions.
- the Ese protein or other antigen may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof.
- the immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectivess.
- Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.
- the immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.
- the knowledge of mammalian Esel and Ese2 cDNA sequences provides for screening by conventional methods to obtain the corresponding human sequences and thus screening for various diseases involving abnormal Esel or Ese2 (or alternative transcripts thereof) in which the defect is due to a mutant Esel or Ese2 gene and thus an altered and abnormal endocytosis process involved in various disorders.
- Mutant forms of the protein may not be able to bind with their normal binding partners and thus endocytosis, vesicular trafficking and/or actin dynamics are negatively affected.
- defects may include, for example, cancer.
- Other defects may include abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.
- Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material.
- the DNA may be isolated and used directly for detection of a specific sequence or may be PCR amplified prior to analysis.
- RNA or cDNA may also be used.
- direct DNA sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are all methods which can be utilized.
- Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non-radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences are then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions of the subject sequence containing identified mutations.
- Direct DNA sequencing reveals sequence differences between normal and mutant Esel or Ese2 DNA.
- Cloned DNA segments may be used as probes to detect specific DNA segments.
- PCR can be used to enhance the sensitivity of this method.
- PCR is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension of the annealed primer with a DNA polymerase. This results in an exponential increase of the target DNA.
- Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.
- Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis. Alternatively fluorography may be employed.
- SUBSTTTUTE SHEET (RULE 26 detection of alteration in electrophoretic mobility of DNA fragments in gels. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. Small deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.
- Nuclease protection assays (SI or ligase-mediated) also reveal sequence changes at specific locations.
- ASO to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used. Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.
- DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes.
- the probe and target sequences may be in solution or the probe sequence may be immobilized. Autoradiography, radioactive decay, spectrophotometry, and fluorometry may also be used to identify specific individual genotypes.
- the portion of the DNA segment that is informative for a mutation can be amplified using PCR.
- the DNA segment immediately surrounding a specific mutation acquired from peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplified by PCR, the products separated by electrophoresis, and transferred to membrane. Labeled probes are then hybridized to the DNA fragments and autoradiography performed.
- the invention provides pharmaceutical compositions comprising Esel or Ese2 proteins or a functional analogue or mimetic of these proteins or their alternative transcripts for the treatment of certain disorders characterized by abnormal endocytosis and thus cell-signalling due to lack or absence of the proteins. Such disorders may include but are not limited to abnormal cell division, cancer, viral infection, abnormal synaptic transmission as seen in central nervous disorders and abnormal cell differentiation.
- Such compositions as provided herein can be appropriately packaged and targeted to specific cells and/or tissues.
- Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result. This may also vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the Esel or Ese2 proteins, peptides or alternative transcripts (for example EselL and Ese2L) to elicit a desired response in the subject. Dosage procedures may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- pharmaceutically acceptable carrier as used herein is meant one or more compatible solid or liquid delivery systems.
- Some examples of pharmaceutically acceptable carriers are sugars, starches, cellulose and its derivatives, powdered tragacanth, malt, gelatin, collagen, talc, stearic acids, magnesium stearate, calcium sulfate, vegetable oils, polyols, agar, alginic acids, pyrogen-free water, isotonic saline, phosphate buffer, and other suitable non-toxic substances used in pharmaceutical formulations.
- Other excipients such as wetting agents and lubricants, tableting agents, stabilizers, anti-oxidants and preservatives are also contemplated.
- compositions described herein can be prepared by known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable carrier.
- Suitable carriers and formulations adapted for particular modes of administration are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985).
- the compositions include, albeit not exclusively, solutions of the substance in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.
- compositions of the invention may be administered therapeutically by various routes such as by injection or by oral, nasal, buccal. rectal, vaginal, transdermal or ocular routes in a variety of formulations, as is known to those skilled in the art.
- the present invention also enables the analysis of factors affecting the expression of the Esel or Ese2 gene in humans or in animal models.
- the invention further provides a system for screening candidate compounds for their ability to turn on or turn off expression of the Esel or Ese2 gene or to screen compounds which are binding partners of these proteins.
- a cell culture system can be used to identify compounds which activate production of Esel or Ese2 proteins or, once Esel or Ese2 production has been activated in the cells, they can be used to identify compounds which lead to suppression or switching off of Esel or Ese2 protein production. Compounds thus identified are useful as therapeutics in conditions where Esel or Ese2 production is deficient or excessive.
- SUBSTT ⁇ UTE SHEET (RULE 26 Compounds can also be screened in culture for their ability to overcome the effect of Ese protein expression in cell culture, tissue culture or in an animal model.
- the present invention enables also a screening method for compounds of therapeutic utility as antagonists of the biological activity, binding activity, of Esel or Ese2 proteins and their binding partners.
- Those skilled in the art will be able to devise a number of possible screening methods for screening candidate compounds for Esel or Ese2 protein antagonism.
- a screening method may also be based on binding to the Esel or Ese2 protein.
- Such competitive binding assays are well known to those skilled in the art. Once binding has been established for a particular compound, a biological activity assay is employed to determine agonist or antagonist potential.
- Cell-free assays can also be readily designed by those skilled in the art to monitor and measure endocytosis, vesicular trafficking and actin dynamics.
- Ese proteins, Ese complexes including Epsl5, Epsl5R and many of the proteins identified in the screens as well as others identified through similar screens can be targeted for use in therapies to treat diseases including cancer, viral infection based diseases, developmental diseases due to altered cell fate specification and/or division as well as neurological diseases and diseases of altered cell migration and other diseases due to defects in the actin cytoskeleton.
- Ese cloning and plasmids High Stringency screening was used to isolate the two mouse Ese cDNAs by previously described methodology (58).
- Esel was cloned from an adult mouse brain cDNA library using a PCR product from nt 1707-2197 of the coding sequence as probe.
- Ese2 was cloned from a mixed tissue adult mouse cDNA library using a mixture of three probes EST#583881 (Research Genetics Inc.), EST#652549 (Research Genetics Inc.) and a PCR product from nt 2712 to nt 3456 of the Ese2 coding sequence.
- SUBSTTTUTE SHEET (RULE 26 The Esel sequence was obtained from a single clone, whereas the Ese2 reading frame was predicted from the overlap of two cDNA clones.
- the DBL/PH/C2 region of EselL was obtained using PCR with an upstream primer designed from sequences within the DBL/PH domain region: GAAGGAGAACTCAGACCGGCTGGAGTGGAT (this sequence was obtained from one partial EselL clone which we had isolated from a mouse brain cDNA library). This upstream primer was paired with downstream primers for the vector.
- the DBL/PH/C2 region of Ese2L was obtained using PCR with upstream and downstream primers flanking the site in Ese2 where sequence divergence had been noted within an EST clone (upstream Ese2 sequence: GACAGAGGAGCGGTACATGGA and downstream Ese2 sequence: AGCTCCCCTGGTTCTGGCTTC).
- upstream Ese2 sequence GACAGAGGAGCGGTACATGGA
- downstream Ese2 sequence AGCTCCCCTGGTTCTGGCTTC
- the Esel cDNA includes 53 nucleotides of 5' UTR plus a natural Notl site and 288 nucleotides of 3 'UTR plus a small region of polylinker including a Notl site.
- the C-terminus of Esel was removed by replacing all sequences from nt 2209 of the coding sequence to the Xhol site in pcDNA3Esel with TGACTCGAG where the stop codon is in bold and the Xhol site is underlined. This construct codes for amino acids 1 -736 of Ese 1.
- pCDNA3Eps!5 This plasmid was constructed from four pieces. It contains the full length Epsl 5.
- the 5 'UTR of this construct has been constructed to be GGATCCACCATG where a BamHI site is underlined and the start codon is bolded. This BamHI site was fused to the BamHI site in pcDNA3.
- the 3 'UTR in this vector is 204 nt of the mouse natural 3 'UTR fused to a short cloning linker ending in the sequence
- pcDNA3Eps!5 ⁇ C This vector is the same as pcDNA3Eps 15 except that sequences downstream from and including mouse Eps 15 coding nucleotide 1500 have been replaced with CCTGGATTACAAGGATGATGATGACAAATGACTCGAG where the first underlined sequence codes for the Flag-epitope, an inframe stop codon is bolded and an Xhol site is underlined. This Xhol site was fused to the polylinker in pcDNA3. The resulting plasmid encodes amino acids 1-501 of mouse Eps 15 fused to a C- terminal Flag epitope. The 5' end of Eps 15 in this construct is as indicated above for pcDNA3Epsl5.
- pGBT9Eselcc The Esel sequence coding for amino acids 330 to 732 were fused directly to
- This plasmid encodes the bait for our SH3 screen. It encodes all five SH3 domains from amino acid 665-1213 and was subcloned into pGBT9 on an EcoRI fragment which fuses the Esel SH3 region in frame with the DBD of GAL4.
- This plasmid codes for the N-terminal 393 amino acids of Esel, including both EH domains. It was subcloned into pGBT9 on an EcoRI/Sall fragment.
- PEG4000 100 mM LiAc, 10 mM Tris-HCl (pH 7.5) as per standard protocols.
- Cells were plated onto Sc-Trp drop-out media. Single colonies were isolated and expression of bait was analyzed by Western Blot using antibodies against the GAL4 DBD. A clone expressing the bait fusion was used to inoculate a 100 mL Sc-Trp liquid culture grown overnight at 30°C. Cells were then re-inoculated into YPD at a density of 5x10 ⁇ cells/mL and grown at 30°C until the titer reached 2x10? cells/mL.
- Colonies were picked, patched and grown at 30°C overnight on Whatman filter paper laid on top of Sc-Trp-Leu-His plates. Filters were submerged in liquid nitrogen for 15 seconds then placed on top of blotting paper soaked in Z-buffer + X-gal. ⁇ -galactosidase activity was measured by the appearance of blue colour. Plasmids from ⁇ -galactosidase positive colonies were shuttled to bacteria by electroporation and isolated for sequencing.
- a multiple tissue northern blot (Clontech) was prehybridized in 5 mL of
- Antigen-Antibody complexes where purified on anti-rabbit agarose or anti- mouse agarose (Sigma Chemical Co.) Samples were run on 7.5% PAGE gels and transferred to nitrocellulose membranes. Filters were blocked in 5% dry milk powder/0.05% Tween 20/PBS, washed in 1% dry milk powder/0.05% Tween 20/PBS, and probed with the appropriate antisera at lmg/ml in wash buffer (In the case of chicken anti-Ese 1 we used lO ⁇ g/ml to probe western blots).
- Probed filters were further washed, probed again with 1/5000 dilution of horseradish peroxidase conjugated anti-rabbit IgG, anti-mouse IgG antibodies (Amersham), or anti-chicken- IgY (Zymed); washed and signal detected using the Enhanced Chemiluminescence detection system as per manufacturers instructions (Amersham).
- Rabbit anti-Ese 1 antisera was raised against a peptide of the following sequence: MAQFPTPFGGSLDVWAITVEE. The antisera was affinity purified over the same peptide (Research Genetics). This peptide was also used at 5 ⁇ g to compete for the 5 ⁇ g of antibody per immunoprecipitation reaction.
- Chicken anti-Ese 1 antisera was raised against a fusion protein between GST and amino acids 665-1213 of mouse Ese 1. This sera was cleared of antibodies reacting against GST by incubation with glutathione s-transferase on glutathione agarose beads.
- Rabbit antibodies have also been raised against a peptide encoding the first twenty one amino acids of mouse Ese2. These antibodies were affinity purified and used to immunoprecipitate endogenous Esel containing protein complexes from cultured PC 12 cells. A protein of approximately 130 kDa was co-immunoprecipitated in complex with Ese2. This protein was isolated from a silver stained gel slice, digested with trypsin and the resulting peptide fragments were analyzed using both MALDI-TOF and Q-TOF Mass Spectrometers. Taken together, these mass spec analyses revealed that the Ese-2 binding protein in question is a Rho-Family exchange protein variably known as KIAA0362, Dbs and Ost.
- the gene encoding KIAA0362, Dbs and Ost proteins is subject to complex alternative splicing but each protein is predicted to contain the DBL/PH exchange domain.
- Ese proteins are found in complex with exchange proteins for the Rho-family of small GTP-binding proteins.
- Monoclonal antibodies against Ese proteins were produced by immunizing mice with a GST fusion protein encoding the Esel C-terminus (from amino acid 665 to the stop codon) according to standard protocols. After multiple injections, the mouse spleens were removed and resuspended in phosphate buffered saline (PBS). The spleen cells served as a source of lymphocytes. These lymphocytes were fused with a permanently growing myeloma partner cell, and the products of the fusion were plated into 96well plates in the presence of selective media. The culture supernatents were then screened by ELISA to identify those containing cells which were secreting anti-Ese antibodies.
- PBS phosphate buffered saline
- Cos-1 cells were typically plated at a density of 2x10 3 per 22x50mm coverglass and transfected with 2.5 ⁇ g of plasmid using Superfect (Qiagen Inc.). After 2 hours, the cells were washed with 10%>FBS in Iscove's Media and fed with fresh 10%FBS in Iscove's Media. Two days later, these cultures where fixed with cold methanol for 30 minutes at room temperature. Cultures were washed three times 10 minutes with Phosphate buffered saline (PBS), blocked for one hour at room temperature with 1%BSA in PBS and then incubated with primary antibody in blocking solution for one hour, also at room temperature.
- PBS Phosphate buffered saline
- Mouse anti-myc monoclonal 9E10 (lO ⁇ g/ml: Santa Cruz Biotech.), Rabbit anti-myc (5 ⁇ g/ml: Upstate Biotechnology Inc.), Rabbit anti- Epsl5 antisera #C20 (l ⁇ g/ml: Santa Cruz Biotech), Rabbit anti-Flag epitope antisera (5 ⁇ g/ml: Zymed) and mouse anti-Dynamin I #D25520, which recognizes Dynamin in Cos-1 cells by both immunoprecipitation and western blotting (data not shown) (20 ⁇ g/ml: Transduction labs, Inc.) were used.
- Novel Ese-coiled-coil interacting clones Mouse homologue of C07E3.1 protein (clone 65): - Sequence ID NO:9
- Mouse partial C07E3.1 protein (clone 65): - Sequence ID NO: 10 GTKSFMDFGSWERHTKGIGQKLLQKMGYVPGRGLGKNAQGIINPIEAKQRKG KGAVGAYGSERTTQSLQDFPVADSEEEAEEEFQKELSQWRKDPSGSKKKPKY SYKTVEELKAKGRVSKKLTAPQKELSQVKVIDMTGREQKVYYS YSQISHKHS VPDEGVPLLAQLPPTAGKEARMPGFALPELEHNLQLLIERTEQEIIQSDRQLQY ERDMVVSLSHELEKTAEVLAHEERVISNLSKVLALVEECERRMQPHGTDPLT LDECARIFETLQDKYYEEYRLADRADLAVAIVYPLVKDYFKDWHPSR
- Murine EselL protein Sequence ID NO: 24
- Murine Ese2L coding Sequence ID NO: 26
- Mouse Ese2L protein Sequence ID NO:27 MAQFPTAMNGGPNMWAITSEERTKHDKQFDNLKPSGGYITGDQARTFFLQS GLPAPVLAEIWALSDLNKDGKMDQQEFSIAMKLIKLKLQGQQLPVVLPPIMK QPPMFSPLISARFGMGSMPNLSIHQPLPPVAPIATPLSSATSGTSIPPLMMPAPL VPSVSTSSLPNGTASLIQPLSIPYSSSTLPHASSYSLMMGGFGGASIQKAQSLID LGSSSSTSSTASLSGNSPKTGTSEWAVPQPSRLKYRQKFNSLDKGMSGYLSGF QARNALLQSNLSQTQLATIWTLADIDGDGQLKAEEFILAMHLTDMAKAGQPL PLTLPPELVPPSFRGGKQVDSVNGTLPSYQKTQEEEPQKKLPVTFEDKRKANY ERGNMELEKRRQVLMEQQREAERKAQKEKEEWERKQRELQEQ
- end7 mutations that cause actin delocalization and block the intemalization step of endocytosis in Saccharomyces cerevisiae. Molecular Biology of the Cell 6: 1721- 1742. 1995.
- the END3 gene encodes a protein that is required for the intemalization step of endocytosis and for actin cytoskeleton organization in yeast. Mol. Biol. Cell. 5: 1023-1037, 1994.
- Tvrosine kinase substrate EPS 15 is constitutively associated with the plasma membrane adaptor AP2. J. Cell Biol. 131: 1831-1838. 1995.
- Epsl5R is a tvrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated intemalization. Journal of Biological Chemistry 2 ⁇ 3: 3003-3012. 1998.
- Panlp and End3p are components of a complex that plays a dual role in organization of the cortical actin cytoskeleton and endocytosis in Saccharomyces cerevisiae. Mol. Cell. Biol. H: 4294-4304. 1997.
- Amphiphysin II (SH3P9:BIN1), a member of the Amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and Nodes of Ranvier in brain and around T Tubules in skeletal muscle. Journal of Cell Biology 137: 1355-1367, 1997.
- Epsin is an EH-domain binding protein implicated in clathrin- mediated endocytosis. Nature. 394, 793-797.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/674,237 US7118886B1 (en) | 1998-04-27 | 1999-04-27 | Ese genes and proteins |
AU36950/99A AU3695099A (en) | 1998-04-27 | 1999-04-27 | Ese genes and proteins |
CA002326601A CA2326601A1 (en) | 1998-04-27 | 1999-04-27 | Ese genes and proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2230201 CA2230201A1 (en) | 1998-04-27 | 1998-04-27 | Ese genes and proteins |
CA2,230,201 | 1998-04-27 | ||
US11873999P | 1999-02-05 | 1999-02-05 | |
US60/118,739 | 1999-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999055728A2 true WO1999055728A2 (en) | 1999-11-04 |
WO1999055728A3 WO1999055728A3 (en) | 1999-12-23 |
Family
ID=25680060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000375 WO1999055728A2 (en) | 1998-04-27 | 1999-04-27 | Ese genes and proteins |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3695099A (en) |
WO (1) | WO1999055728A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999053062A2 (en) * | 1998-04-16 | 1999-10-21 | Cedars-Sinai Health System, Et Al | Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
WO2002033122A1 (en) * | 2000-10-13 | 2002-04-25 | Genox Research, Inc. | Method of examining allergic diseases |
WO2003034896A2 (en) * | 2001-10-12 | 2003-05-01 | Beth Israel Deaconess Medical Center, Inc. | Methods of diagnosis of autoimmune disease |
US7849929B2 (en) | 2008-05-12 | 2010-12-14 | Longyear Tm, Inc. | Drill rod spinner device |
US7997166B2 (en) | 2007-06-15 | 2011-08-16 | Longyear Tm, Inc. | Methods and apparatus for joint disassembly |
US7997167B2 (en) | 2007-08-30 | 2011-08-16 | Longyear Tm, Inc. | Clamping and breaking device |
US8006590B2 (en) | 2008-05-12 | 2011-08-30 | Longyear Tm, Inc. | Open-faced rod spinner |
US9593543B2 (en) | 2013-12-30 | 2017-03-14 | Bly Ip Inc. | Drill rod handling system for moving drill rods to and from an operative position |
US10066451B2 (en) | 2015-12-22 | 2018-09-04 | Bly Ip Inc. | Drill rod clamping system and methods of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031625A1 (en) * | 1995-04-07 | 1996-10-10 | Cytogen Corporation | Polypeptides having a functional domain of interest and methods of identifying and using same |
US5717067A (en) * | 1992-08-25 | 1998-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Substrate for the epidermal growth factor receptor kinase |
-
1999
- 1999-04-27 AU AU36950/99A patent/AU3695099A/en not_active Abandoned
- 1999-04-27 WO PCT/CA1999/000375 patent/WO1999055728A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5717067A (en) * | 1992-08-25 | 1998-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Substrate for the epidermal growth factor receptor kinase |
WO1996031625A1 (en) * | 1995-04-07 | 1996-10-10 | Cytogen Corporation | Polypeptides having a functional domain of interest and methods of identifying and using same |
Non-Patent Citations (6)
Title |
---|
DATABASE EMEST23 [Online] E.M.B.L. Databases Accession Number: AA217338, 11 February 1997 (1997-02-11) MARRA M ET AL: "Mus musculus cDNA clone 652549 5' similar to SW:EP15_Mouse P42567 EPIDERMAL GROWTH FACTOR RECEPTOR SUBSTRATE 15" XP002117202 * |
DATABASE EMEST24 [Online] E.M.B.L. Databases Accession Number: AA061808, 24 September 1996 (1996-09-24) MARRA M ET AL: "Mus musculus cDNA clone 483558 5' similar to TR:G968973 G968973 EPS15R" XP002117201 * |
DATABASE EMVRT [Online] E.M.B.L. Databases Accession Number: AF032118, 27 November 1997 (1997-11-27) YAMABHAI M ET AL: "Intersectin, a novel adaptor protein with two eps15 homology and five src homology 3 domains" XP002117200 cited in the application -& YAMABHAI M ET AL: "Intersectin, a novel adaptor protein with two Eps15 homology and five Src homology 3 domains" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 273, no. 47, 20 November 1998 (1998-11-20), pages 31401-31407, XP002117205 * |
GUIPPONI M ET AL: " "Two isoforms of a human intersectin (ITSN) protein are produced by brain-specific alternative splicing in a stop codon" GENOMICS, vol. 53, no. 3, 1 November 1998 (1998-11-01), pages 369-376, XP002117198 * |
SALCINI A ET AL: "Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module" GENES & DEVELOPMENT, vol. 11, no. 17, 1 September 1997 (1997-09-01), pages 2239-2249, XP002117199 cited in the application * |
SENGAR A ET AL: "The EH and SH3 domain Ese proteins regulate endocytosis by linking to dynamin and Eps15" EMBO JOURNAL., vol. 18, no. 5, 1 March 1999 (1999-03-01), pages 1159-1171, XP002117197 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999053062A2 (en) * | 1998-04-16 | 1999-10-21 | Cedars-Sinai Health System, Et Al | Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
WO1999053062A3 (en) * | 1998-04-16 | 2000-04-20 | Cedars Sinai Health System | Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
WO2002033122A1 (en) * | 2000-10-13 | 2002-04-25 | Genox Research, Inc. | Method of examining allergic diseases |
WO2003034896A2 (en) * | 2001-10-12 | 2003-05-01 | Beth Israel Deaconess Medical Center, Inc. | Methods of diagnosis of autoimmune disease |
WO2003034896A3 (en) * | 2001-10-12 | 2004-04-22 | Beth Israel Hospital | Methods of diagnosis of autoimmune disease |
US7997166B2 (en) | 2007-06-15 | 2011-08-16 | Longyear Tm, Inc. | Methods and apparatus for joint disassembly |
US7997167B2 (en) | 2007-08-30 | 2011-08-16 | Longyear Tm, Inc. | Clamping and breaking device |
US7849929B2 (en) | 2008-05-12 | 2010-12-14 | Longyear Tm, Inc. | Drill rod spinner device |
US8006590B2 (en) | 2008-05-12 | 2011-08-30 | Longyear Tm, Inc. | Open-faced rod spinner |
US8291791B2 (en) | 2008-05-12 | 2012-10-23 | Longyear Tm, Inc. | Open-faced rod spinning device |
US9593543B2 (en) | 2013-12-30 | 2017-03-14 | Bly Ip Inc. | Drill rod handling system for moving drill rods to and from an operative position |
US10047576B2 (en) | 2013-12-30 | 2018-08-14 | Bly Ip Inc. | Drill rod handling system for moving drill rods to and from an operative position |
US10066451B2 (en) | 2015-12-22 | 2018-09-04 | Bly Ip Inc. | Drill rod clamping system and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
AU3695099A (en) | 1999-11-16 |
WO1999055728A3 (en) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8258271B2 (en) | mTOR kinase-associated proteins | |
US20090023645A1 (en) | AIB1, a novel steroid receptor co-activator | |
US6441156B1 (en) | Calcium channel compositions and methods of use thereof | |
AU2578401A (en) | Bcl-g polypeptides, encoding nucleic acids and methods of use | |
WO1999055728A2 (en) | Ese genes and proteins | |
EP1017812A1 (en) | Telomere repeat binding factors and diagnostic and therapeutic use thereof | |
US20040010812A1 (en) | Human hyaluronan receptor | |
US6987004B1 (en) | Genes integrating signal transduction pathways | |
US7118886B1 (en) | Ese genes and proteins | |
US7507801B2 (en) | Adapter gene | |
US20070101450A1 (en) | High-affinity choline transporter | |
WO1999036548A1 (en) | Human lymphoid protein tyrosine phosphatases | |
CA2326601A1 (en) | Ese genes and proteins | |
US20030104443A1 (en) | AFAP sequences, polypeptides, antibodies and methods | |
CA2309677A1 (en) | Novel gene and protein expressed in neural and pancreatic tissues | |
CA2230201A1 (en) | Ese genes and proteins | |
WO2000029578A1 (en) | Cloning and characterization of two m-rna transcription factors | |
WO2001051509A2 (en) | Shc-associated protein 140 (sap-140) | |
WO2002020786A2 (en) | Kinase d interacting protein | |
US20050042631A1 (en) | Cloning and characterization of two novel m-RNA transcription factors | |
JP2003144168A (en) | Cell cycle-relating protein having nuclear export function or nucleus-cytoplasm transport function | |
US20050130887A1 (en) | Genetic sequence related to bone diseases | |
CA2429856A1 (en) | Adapter protein and gene encoding it | |
JP2004073142A (en) | Ganp binding protein | |
WO2000012046A2 (en) | Pkdl nucleic acids, polypeptides, and diagnostic and therapeutic methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2326601 Country of ref document: CA Kind code of ref document: A Ref document number: 2326601 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09674237 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |